TOVX (Theriva Biologics) EBITDA Margin %: -701.00% (As of Mar. 2026)

What is Theriva Biologics EBITDA Margin %?

Theriva Biologics TOVX -0.46% 28 EBITDA Margin % is -701.00% as of Mar. 2026. GuruFocus rates TOVX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Theriva Biologics ranks worse than 92.28% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Theriva Biologics's EBITDA for the three months ended in Mar. 2026 was $-2.10 Mil. Theriva Biologics's Revenue for the three months ended in Mar. 2026 was $0.30 Mil. Therefore, Theriva Biologics's EBITDA margin for the quarter that ended in Mar. 2026 was -701.00%.

Theriva Biologics (AMEX:TOVX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Theriva Biologics EBITDA Margin % Related Terms

Theriva Biologics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics EBITDA Margin % Chart

Theriva Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

Theriva Biologics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	-701.00

TOVX vs CALC, PHIO, PHGE: EBITDA Margin % Comparison

For the Biotechnology subindustry, Theriva Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theriva Biologics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's EBITDA Margin % falls into.

Save Embed

28GF Score

Theriva Biologics Inc TOVX

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Theriva Biologics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Theriva Biologics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-23.943	/	0
	=	%

Theriva Biologics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-2.103	/	0.3
	=	-701.00 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -701.00% mean?

Theriva Biologics (TOVX) has a EBITDA Margin % of -701.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Theriva Biologics and its competitors. According to the industry distribution chart, Theriva Biologics ranks #872 out of 945 companies in the Biotechnology industry, placing it in the top 92.3%.

Is Theriva Biologics' EBITDA Margin % too high?

Theriva Biologics' current EBITDA Margin % is -701.00%. Based on the distribution chart, Theriva Biologics ranks #872 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Theriva Biologics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Theriva Biologics' EBITDA Margin % compare to CALC and PHIO?

According to the Biotechnology industry distribution chart, Theriva Biologics ranks #872 out of 945 companies for EBITDA Margin %. This places Theriva Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Theriva Biologics and its competitors. Theriva Biologics's current EBITDA Margin % is -701.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Theriva Biologics stock overvalued right now?

Theriva Biologics (TOVX) has a current EBITDA Margin % of -701.00%. The current EBITDA Margin % is -701.00%. Theriva Biologics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current EBITDA Margin % is -701.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Industry Healthcare Biotechnology

Comparable Companies CALC PHIO PHGE SNGX ERNA CYCN GDTC ZEOX KPRX LNAI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

28GF Score

Get the complete analysis for TOVX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24

Price

View TOVX Analysis

See EBITDA Margin % data for all stocks →